WCLC 2021 | 兩大RET抑制劑中國人群數據出爐( 三 )


1.MA02.01-EfficacyandSafetyofSelpercatinibinChinesePatientsWithRETFusion-PositiveNon-SmallCellLungCancer:APhase2Trial.2021WorldConferenceonLungCancer
2.MA02.02-EfficacyandSafetyofPralsetinibinChinesePatientswithAdvancedRETFusion+Non-SmallCellLungCancer.2021WorldConferenceonLungCancer